Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -21.7% | 2.7% | 10.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67% | 70.1% | 75.1% | 78.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -171.4% | -92.9% | -141.4% | -327.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -207.9% | -121.6% | -188.2% | -245.2% |
| EPS Diluted | -1.45 | -1.1 | -1.68 | -2.07 |
| % Growth | -31.8% | 34.5% | 18.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |